In 2014 there were a number of significant antitrust developments for the pharmaceutical industry. These involved not only challenges with respect to pharmaceutical patent litigation settlements (so-called “reverse payment” agreements), but also investigations and challenges to conduct related to product reformulations, Risk Evaluation and Mitigation Strategies (REMS), and FDA citizen petitioning activity.
Read More: Outlook for 2015: Antitrust Litigation in the Pharma Industry – More Than Just Actavis Progeny